Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04684589
PHASE2

Effect of PDE5 Inhibition on Adipose Metabolism in Humans

Sponsor: Vanderbilt University Medical Center

View on ClinicalTrials.gov

Summary

This is a randomized, double-blinded, placebo-controlled study of the effects of PDE5 inhibition with tadalafil on adipose tissue in obese individuals. Adipose metabolism will be measured using magnetic resonance imaging (MRI) scans and by aspirating a small amount of adipose to measure gene expression.

Key Details

Gender

All

Age Range

19 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

89

Start Date

2021-03-16

Completion Date

2025-06-24

Last Updated

2026-06-18

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Tadalafil 20 MG

Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.

DRUG

Placebo

Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.

Locations (1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States